Preclinical Results of PRT-064040, a Novel Intranasal CGRP Receptor Antagonist for Migraine, Published in Journal of Pharmacology and Experimental Therapeutics
BRILLIANT PHARMACEUTICALS
A High-Quality Developer, Manufacturer, and Distributor of Pharmaceuticals
▲9April 4-5 CBI Biopharmaceutical Innovation Expo Scan QR Code to Register
Note:This article does not constitute any investment advice or recommendations; please refer to official/company announcements for authoritative information.This article is intended solely for the introduction of medications related to medical and health care; it does not constitute a recommendation for treatment plans (if any), nor does it represent the platform's position.Authorization is required for any article reprints.
Recently, Sichuan Puruite Pharmaceutical Co., Ltd. (hereinafter referred to as“Sichuan Brilliant Pharmaceuticals”) Independently developed novel third-generation highly selective calcitonin gene-related peptide（Calcitonin Gene-Related Peptide，CGRP）Receptor AntagonistPRT-064040Preclinical research findings on the nasal spray were published in the Journal of Pharmacology and Experimental Therapeutics(Journal of Pharmacology and Experimental Therapeutics，JPET）Received, and on6Month17Published online[1], marking Sichuan Brilliant PharmaceuticalsPRT-064040The project’s robust preclinical research and its scientific translational value have been recognized by international peer experts.
Figure1. PRT-064040LinBedside ResearchResearch findings in 《JPET》Published
《Journal of Pharmacology and Experimental Therapeutics》(abbreviated asJPET) is a century-old classic and authoritative journal in the field of pharmacological research (founded in1909year), enjoying high recognition within the industry. Its disciplinary positioning focuses on chemical substances-Mechanisms of Interaction in Biological Systems, Receiving Only Dose-Response and Molecular/Cell/Complete pharmacological experimental studies on animal mechanisms. The journal has also published articles by multinational pharmaceutical companies inCGRPandCGRPPreclinical Research Findings on Marketed Drugs Targeting Receptors.
Figure2. PRT-064040Research FindingsIn Press, Journal Pre-proofStage
In recent years, calcitonin gene-related peptide (CGRP) and its receptor have been clinically proven to be important therapeutic targets for migraine. Meanwhile, an increasing number of basic research studies have revealed their significant pathogenic mechanisms in autoimmune diseases, pain, and oncology indications.PRT-064040AsChina's First, the World's SecondCGRPReceptor nasal spray antagonists are expected to provide rapid analgesic effects, offering the advantage of a faster onset of action compared to the oral route, and are more user-friendly and convenient for patients who are reluctant to receive injections. Furthermore, relevant studies have shown thatPRT-064040It also possesses potential differentiated advantages over other marketed nasal spray drugs with the same target. Currently,PRT-064040A Phase II clinical study is currently being conducted among migraine patients in China.
Reference Sources:
DOI: 10.1016/j.jpet.2026.104966 (Article link: https://www.sciencedirect.com/science/article/abs/pii/S0022356526011651)
Declaration:
1. This news release aims to share cutting-edge academic developments and is intended solely for reference by healthcare professionals for academic purposes, not for advertising.
2. This product has not yet been approved for marketing by the National Medical Products Administration (NMPA). The current information is shared solely for dynamic updates during the research and development phase. Sichuan Puruite Pharmaceutical does not recommend any unapproved drugs or indications.
Copyright Notice: This article is reprinted fromFrom BRILLIANT PHARMACEUTICALS, such asMedia outlets or individuals who do not wish their content to be reposted may contact us, and we will remove it immediately.
